Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year delays in access to new antibiotics were common even in high income countries (19 Aug 2021 newsletter with YouTube discussion). But as we’ll learn today, that analysis considers only one
Dear All, As we’ve discussed previously (1 Oct 2024 newsletter), the HLM on AMR at UNGA 2024 is but one stop along the road to global action on AMR (acronymics: HLM on AMR at UNGA 2024 = High-Level Meeting on AMR at the 2024 UN General Assembly). In follow-up, we now have two AMR-related declarations from
Dear All, Back in 2022, I wrote a newsletter about the World Health Organization putting out a call to form a Task Force of AMR Survivors. The Task Force of Antimicrobial Resistance Survivors was established last October and its members have been busy ever since! There are currently 12 members, each serving 2 years, and they
Dear All, The Global Leaders Group on Antimicrobial Resistance (GLG AMR) chaired by Her Excellency Prime Minister Mia Amor Mottley of Barbados is putting out a call for more members! Founded in 2020 by the Quadripartite, the GLG AMR has been fundamental to steady build of global awareness about AMR at senior political levels. One example of their impact
Dear All, MyCARE, a fungal patient advocacy organization, and the Partnership to Fight Infectious Diseases (PFID), are sending a letter to the California Congressional Delegation asking them to weigh in U.S. House and Senate leadership to pass the PASTEUR Act by the end of the year. The state of California has the largest Congressional delegation and
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of
Dear All, BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I’ve never seen one before, but an SSN is market research with which BARDA will “collect feedback from current and prospective antibiotic development partners” that will “serve as continued market research for potential future acquisitions
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All, Greetings from Porto (Portugal) where we’ve just ended the 2024 edition of the ESCMID-ASM Developer’s Meeting .. a superb congress with contributions from EMA, FDA, young investigators, older investigators, and points between. I enjoyed meeting so many of you this week! Three items today, all on the path to next week’s United Nations General Assembly High-Level